Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
259.93B
Market cap259.93B
Price-Earnings ratio
13.85
Price-Earnings ratio13.85
Dividend yield
3.09%
Dividend yield3.09%
Average volume
18.10M
Average volume18.10M
High today
$105.00
High today$105.00
Low today
$104.80
Low today$104.80
Open price
$100.68
Open price$100.68
Volume
16.26K
Volume16.26K
52 Week high
$105.84
52 Week high$105.84
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

The current Merck(MRK) stock price is $104.99, with a market capitalization of 259.93B. The stock trades at a price-to-earnings (P/E) ratio of 13.85 and offers a dividend yield of 3.1%.

During the trading session on 2025-12-23, Merck(MRK) shares reached a daily high of $105.00 and a low of $104.80. At a current price of $104.99, the stock is +0.2% higher than the low and still -0.0% under the high.

Trading volume for Merck(MRK) stock has reached 16.26K, versus its average volume of 18.1M.

Over the past 52 weeks, Merck(MRK) stock has traded between a high of $105.84 and a low of $73.31.

Over the past 52 weeks, Merck(MRK) stock has traded between a high of $105.84 and a low of $73.31.

MRK News

Benzinga 3d
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal

President Donald Trump and nine major pharmaceutical companies announced agreements to lower the cost of medications for cash payers and the government’s Medica...

TipRanks 4d
FDA grants two national priority vouchers

The Food and Drug Administration awarded national priority vouchers under the Commissioner’s National Priority Voucher pilot program to two investigational prod...

The Motley Fool 4d
Better Buy in 2026: Pfizer or Merck?

This year has been one to forget for these pharmaceutical giants. Pfizer (PFE +0.54%) and Merck (MRK +0.17%) are two pharmaceutical giants that have lagged bro...

Better Buy in 2026: Pfizer or Merck?

Analyst ratings

57%

of 28 ratings
Buy
57.1%
Hold
42.9%
Sell
0%

More MRK News

Benzinga 4d
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out

Merck & Co. Inc. (NYSE:MRK) will not exercise its option for Evaxion A/S (NASDAQ:EVAX) Gonorrhea vaccine candidate EVX-B2. Gonorrhoea is a common, sexually tra...

Benzinga 5d
Merck Cholesterol, Cancer Drugs May Enter FDA Fast-Track Program: Report

The U.S. Food and Drug Administration (FDA) is preparing to fast-track reviews of two experimental Merck & Co. Inc. (NYSE:MRK) drugs with potential blockbuster...

24/7 Wall St. 5d
Wall Street Analysts Upgrade GE Vernova, Micron, Merck and Rivian While Downgrading Lennar and Realty Income

Here Are Thursday’s Top Wall Street Analyst Research Calls: Digital Realty, GE Vernova, Micron Technology, Merck & Co., Rivian, United Airlines, and More Quick...

TipRanks 5d
Merck upgraded to Outperform from Market Perform at BMO Capital

BMO Capital upgraded Merck (MRK) to Outperform from Market Perform with a price target of $130, up from $82. The firm says the company is assembling a portfolio...

Benzinga 6d
Merck's Keytruda-Padcev Combo Boosts Survival In Pivotal Bladder Cancer Trial

Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladd...

Benzinga 6d
Pfizer, Merck Are Boring Again: 2026 Investors Are Circling Back - Merck & Co, Pfizer - Benzinga

...

Pfizer, Merck Are Boring Again: 2026 Investors Are Circling Back - Merck & Co, Pfizer - Benzinga
Benzinga 6d
Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

Pfizer Inc (NYSE:PFE) and Merck & Co Inc (NYSE:MRK) aren't exciting stocks anymore — and after a bruising reset, that's starting to look intentional. Pfizer's s...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.